Navigation Links
CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
Date:1/29/2009

BRANFORD, Conn., Jan. 29 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), today reported its financial results for the fourth quarter and calendar year of 2008 and provided milestone and financial guidance for the first half of 2009.

During the three month period ended December 31, 2008, CuraGen utilized $3.8 million of cash and investments and ended the fourth quarter with $88 million of cash and investments. At December 31, 2008, CuraGen has outstanding $19 million of 4% convertible subordinated notes due February 2011 with a market value of approximately $15 million. For the quarter ended December 31, 2008, CuraGen reported total operating expenses of $4.1 million, compared to total operating expenses of $11.1 million during the same period in 2007. Included in fourth quarter operating expenses is approximately $0.5 million of restructuring charges for a reduction in work force undertaken in December 2008.

"We currently have $88 million of cash and investments on hand and an attractive Phase II development asset that shows activity in metastatic melanoma and promise in breast cancer." commented Dr. Timothy M. Shannon, President and Chief Executive Officer. "We are encouraged by the activity CR011-vcMMAE has demonstrated to date and we will be releasing additional data on our two ongoing trials in the second quarter of 2009" commented Dr. Shannon.

2009 Milestones and Financial Guidance

The following statements are based on CuraGen's current expectations. These statements are forward-looking and actual results may differ materially. Please see the note regarding Forward-Looking Statements in this release for a description of certain important risk factors that could cause actual results to differ and refer to CuraGen's periodic reports on file with the Securities and Exchange Commission for a more complete descrip
'/>"/>

SOURCE CuraGen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. CuraGen Reports Third Quarter 2008 Financial Results
2. CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million
3. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
4. CuraGen to Present at the BIO CEO & Investor Conference
5. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
6. CuraGen Corporation Receives Notification from NASDAQ
7. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
8. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
9. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
10. CuraGen Appoints Clinical Oncologist as VP of Medical Development
11. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... 29, 2015 , ... Asymmetrex, LLC founder and ... the full range of capabilities of its unique cache of technologies for identifying, ... day-to-day renewal and repair of normal tissues and organs. This property makes them ...
(Date:7/28/2015)... A n ... rapidly developing and commercialising innovative medicines to transform patient quality ... Highly experienced management team; blue chip ... Mereo BioPharma Group Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, ... £76.5m), gross, from blue chip institutional investors and simultaneously acquired ...
(Date:7/28/2015)... Virginia (PRWEB) , ... July 29, 2015 , ... The new Xsample 530 sample ... It handles a wide range of liquid viscosities – from less than 12,000 mPas (internal ... 12 mL vials. , What immediately catches the eye about Xsample 530 is its ...
(Date:7/28/2015)... YORK , July 28, 2015 People ... by hearing aids achieved significant and sometimes profound improvements ... cochlear implant devices, according to a new multicenter study ... In the study, described online ahead of print in ... medical centers and private clinics in the ...
Breaking Biology Technology:Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11New Moves in Automatic Sample Handling: Introducing Xsample 530 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3
... of technologies showcased at the American Society for, Therapeutic Radiology and ... ... 2008, BOSTON, Sept. 22 ASTRO Booth # 547 -- Varian,Medical ... cancer and other disorders, is showcasing a full,spectrum of technologies and products ...
... Delivery Enable CyberKnife Centers ... Increasing Demand for Radiosurgery, SUNNYVALE, Calif., Sept. 22 ... in the field of radiosurgery,announced today that Oklahoma CyberKnife ... dramatically reduced treatment,planning and delivery times over the last ...
... from Varian Medical Systems and BrainLAB enabling, non-invasive treatment of ... ... system, PALO ALTO, Calif., and WESTCHESTER, Ill., Sept. ... of stereotactic body radiosurgery (SBRT) for the treatment,of cancer and other conditions. ...
Cached Biology Technology:Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment 2Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment 3Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment 4Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 2Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 3Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 4Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 2Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 3Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 4Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 5
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
(Date:7/7/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a biometric ... revised version of one of its first 30 second commercials will ... New York , Chicago , ... metro areas.    , , , , ... the cards in your wallet and keep your identity secure. ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... the European Commission,s in-house science service, the Joint Research Centre ... on how to assess the environmental impacts of products and ... Europe and aims to help design more sustainable products, which ... limited resources. , The increasing world population and the ...
... Researchers have created an ultrasensitive biosensor that could ... cancer and "personalized medicine" tailored to the specific ... could be several hundred times more sensitive than ... different types of sensors, said Muhammad A. Alam, ...
... soil can remain open underground even after they have ... found. The results could have important implications for ... and pesticide applications. "These soils are very ... Australia," said lead author Dr Anna-Katrin Greve, a postdoctoral ...
Cached Biology News:A practical guide to green products and services 2Ultrasensitive biosensor promising for medical diagnostics 2Secret soil cracks linger, despite surface sealing 2